<SEC-DOCUMENT>0001070081-17-000055.txt : 20170302
<SEC-HEADER>0001070081-17-000055.hdr.sgml : 20170302
<ACCEPTANCE-DATETIME>20170302081357
ACCESSION NUMBER:		0001070081-17-000055
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170302
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170302
DATE AS OF CHANGE:		20170302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		17656990

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9548C69B8170F3BAC2608D331EE45F93"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;">&#160;</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:240%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported):  March 2, 2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">PTC THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact Name of Company as Specified in Charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-35969</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">04-3416587</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction <br>of Incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission <br>File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer <br>Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">100 Corporate Court</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">South Plainfield, NJ</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">07080</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Company&#8217;s telephone number, including area code:  </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(908) 222-7000</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Not applicable</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">see</font><font style="font-family:inherit;font-size:10pt;">&#32;General Instruction A.2. below):</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:100%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01. &#160;&#160;&#160;&#160;Regulation FD Disclosure.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 2, 2017, PTC Therapeutics, Inc. (&#8220;PTC&#8221; or the &#8220;Company&#8221;) issued a press release announcing the results from ACT CF, its Phase 3, double-blind, placebo-controlled, 48-week clinical trial to evaluate the efficacy and safety of ataluren (brand name: Translarna</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">) in patients with cystic fibrosis caused by nonsense mutations, or nmCF. PTC will host a conference call Thursday, March 2, 2017, at 9:00 a.m. ET to discuss the results of ACT CF.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The full text of the press release announcing the results of ACT CF as well as information on how to access the conference call is attached as Exhibit 99.1 hereto and is incorporated by reference into this Item 7.01.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information set forth in or incorporated by reference into this Item 7.01 shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01.  &#160;&#160;&#160;&#160;Other Events.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 2, 2017, the Company announced that the primary and secondary endpoints were not achieved in ACT CF. </font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the intent-to-treat population, the primary endpoint of lung function as measured by absolute change in percent-predicted FEV1 (forced expiratory volume in one second), over 48 weeks from baseline, there was a 0.6% difference in favor of ataluren versus placebo (-1.4% change on ataluren versus -2.0% change on placebo; p=0.534). For the secondary endpoint of rate of pulmonary exacerbations, there was a trend in favor of ataluren, with the rate in the ataluren group being 14% lower than the placebo group (p=0.401). The results were not statistically significant.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01.  Financial Statements and Exhibits. </font></div><div style="line-height:120%;text-align:left;padding-left:78px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)</font><font style="font-family:inherit;font-size:3pt;">&#32;&#160;&#160;&#160;&#160;  </font><font style="font-family:inherit;font-size:10pt;">Exhibits:</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1 &#160;&#160;&#160;&#160;Press Release dated March 2, 2017</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:17px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.88194444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:13%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PTC THERAPEUTICS, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 2, 2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Shane Kovacs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shane Kovacs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:20%;"></td><td style="width:6%;"></td><td style="width:74%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:center;padding-left:24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:center;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:24px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Release dated March 2, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:12px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s60956ABA8398C0AF5C3E8DD067730A2D"></a></div><div></div><div><br></div><div style="line-height:138%;padding-bottom:10px;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Exhibit 99.1</font></div><div style="line-height:138%;padding-bottom:10px;text-align:left;"><img src="exhibit991image1.jpg" alt="exhibit991image1.jpg" style="height:56px;width:92px;"></div><div style="line-height:138%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">PTC Therapeutics Announces Results from Pivotal Phase 3 Clinical Trial of Ataluren in Patients Living with Nonsense Mutation Cystic Fibrosis </font></div><div style="line-height:138%;text-align:center;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- ACT CF trial missed primary and secondary endpoints - </font></div><div style="line-height:138%;text-align:center;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- Company to host conference call today, March 2</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">nd</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;at 9:00 am ET -</font></div><div style="line-height:138%;padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SOUTH PLAINFIELD, N.J., March 2, 2017</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the Ataluren Confirmatory Trial (ACT CF) in nonsense mutation cystic fibrosis (nmCF) did not achieve its primary or secondary endpoints. Ataluren was generally well tolerated and ACT CF confirmed a favorable safety profile for ataluren, which has now been used by more than 1,000 patients across multiple indications. PTC plans to discontinue current clinical development of ataluren in cystic fibrosis, close ongoing extension studies and withdraw its application for marketing authorization in cystic fibrosis in Europe. </font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;We are disappointed with the outcome of this trial as there are no treatments that target the underlying cause of nonsense mutation cystic fibrosis, one of the most difficult forms to treat,&#8221; said Stuart W. Peltz, Ph.D., chief executive officer of PTC Therapeutics. &#8220;We are particularly grateful to patients and investigators who participated in our trials. We remain committed to patients receiving ataluren in other indications.&#8221; </font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ACT CF was a double-blind, placebo-controlled, 48-week clinical trial comparing ataluren to placebo in nmCF patients six years of age or older not receiving chronic inhaled aminoglycosides. The Phase 3 study, conducted in 16 countries, enrolled 279 patients who were randomized to receive either ataluren or placebo. In the intent-to-treat population, the primary endpoint of lung function as measured by absolute change in percent-predicted FEV1 (forced expiratory volume in one second), over 48 weeks from baseline, there was a 0.6% difference in favor of ataluren versus placebo (-1.4% change on ataluren versus -2.0% change on placebo; p=0.534). For the secondary endpoint of rate of pulmonary exacerbations, there was a trend in favor of ataluren, with the rate in the ataluren group being 14% lower than the placebo group (p=0.401). The results were not statistically significant.  </font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The safety profile of ataluren in the ACT CF study was consistent with previous studies and no new safety signals were identified. </font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Cystic Fibrosis </font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cystic fibrosis is among the most common life-threatening genetic disorders worldwide. It is caused by defects in a single gene known as the cystic fibrosis transmembrane conductance regulator, or CFTR. The CFTR gene encodes the CFTR protein, which is used by the body to transport chloride across cell membranes. Genetic mutations that result in the loss of function of the CFTR protein cause the body to produce abnormally thick and sticky mucus that clogs multiple organs, including the lungs, pancreas and liver. In particular, the absence or very low levels of CFTR leads to progressive loss of lung function, potentially life-threatening lung infections, permanent pancreatic damage and malnutrition because digestive enzymes from the pancreas do not reach the intestines to help break down and absorb food. The average age of death for CF patients is in their mid-thirties.</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About ataluren (Translarna&#8482;) </font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ataluren (brand name: Translarna</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">TM</sup></font><font style="font-family:inherit;font-size:12pt;">), discovered and developed by PTC Therapeutics, Inc., is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne muscular dystrophy. Ataluren is licensed in the European Economic Area for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. Ataluren is an investigational new drug in the United States. The development of ataluren has been supported by grants from Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation); Muscular Dystrophy Association; FDA's Office of Orphan Products Development; National Center for Research Resources; National Heart, Lung, and Blood Institute; and Parent Project Muscular Dystrophy. </font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About PTC Therapeutics </font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA, or mRNA, molecule is copied from DNA through the transcription process. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. For more information on the company, please visit our website www.ptcbio.com.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Today's Conference Call</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">The call can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 82242185. </font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for two weeks. </font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:130%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">For More Information: </font></div><div style="line-height:130%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:130%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Investors: </font></div><div style="line-height:130%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Emily Hill</font></div><div style="line-height:130%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">+1 (908) 912-9327</font></div><div style="line-height:130%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">ehill@ptcbio.com </font></div><div style="line-height:130%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:130%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Media: </font></div><div style="line-height:130%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Jane Baj</font></div><div style="line-height:130%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">+1 (908) 912-9167</font></div><div style="line-height:130%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">jbaj@ptcbio.com </font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Forward-looking Statements&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements, other than those of historical fact, contained in this release are forward-looking statements, including statements regarding the future expectations, plans and prospects for PTC, with respect to regulatory and clinical actions or otherwise; the clinical utility and potential advantages of Translarna (ataluren); PTC's strategy, future operations, future financial position, future revenues or projected costs; and the objectives of management.&#160; Other forward-looking statements may be identified by the words "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.</font></div><div style="line-height:138%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to PTC's scientific approach and general development progress; the outcome of ongoing or future clinical studies in Translarna and PTC&#8217;s other product candidates; expectations for regulatory approvals; PTC's ability to meet existing or future regulatory standards with respect to Translarna; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; PTC's ability to maintain its marketing authorization of </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in the European Economic Area (EEA), including whether the European Medicines Agency (EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC&#8217;s ability to enroll, fund, complete and timely submit to the EMA the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open label extension;&#160; PTC&#8217;s ability to resolve the matters set forth in the Refuse to File letter it received from the United States Food and Drug Administration (FDA) in connection with its New Drug Application (NDA) for Translarna for the treatment of nmDMD, including whether filing the NDA over protest with the FDA will result in a timely or successful review of the NDA, and whether PTC will be required to perform additional clinical and non-clinical trials or analyses at significant cost;&#160;the eligible patient base and commercial potential of Translarna and PTC's other product candidates;&#160;PTC's ability to commercialize and commercially manufacture Translarna in general and specifically as a treatment for nmDMD; the outcome of pricing and reimbursement negotiations in those territories in which PTC is authorized to sell Translarna for the treatment of nmDMD; and the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q as well as any updates to these risk factors filed from time to time in PTC's other filings with the&#160;SEC. You are urged to carefully consider all such factors.</font></div><div style="line-height:138%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that Translarna will receive full regulatory approval in any territory or maintain its current marketing authorization for Translarna for the treatment of nmDMD in the EEA, or prove to be commercially successful in general, or specifically with respect to the treatment of nmDMD.</font></div><div style="line-height:138%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exhibit991image1.jpg
<TEXT>
begin 644 exhibit991image1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 Z17AI9@  34T *@    @  U$0  $
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M100V2@ 5R0I_L)\,>&=-\$^&]/T71M/L=)T?2;:.RL;&R@6WMK*"-0D<44:
M*D:*H554      5_-_\ \&IWPOTKQ_\ \%2)M6U".62\\#^#-2UO3&20J([A
MY;:P8L!]X>1>SC!XR0>H%?TG5XN93;J*/9$R"BBBO-)"BBB@ HHHH **** "
MBBB@#X/_ &S?!W_""?'S5/*CCBMM95-3A <L29,B0G/0F993CH 1C X'E)N_
M>OI;_@IAI$=O>^$=22W_ 'TT=U;33A3RJF)HT)Z<%Y2![M7RP;K%?S+Q;@8X
M;.*]*.W-?_P)*7X7/ZOX+Q4L9DF'K2WY>5_]NMQ_&UR^UU[UV?[/7Q+_ .%8
M_&/0M5>98;1;@07C.6V""3Y)&8+R=H;>!SRHXXKSPW5--UG^*O%PE>>'K0Q%
M/XHM->J=SZ'%X&&)H3P]7X9II^C5F?JU17*_ SQE_P + ^#WAK6&N/M4UYI\
M1N)<8W3JH67_ ,B*P_"NJK^KL/6C6I1K0VDDUZ-7/XVQ6'G0K3H5-XMI^J=F
M%%%%;& 4444 %?$/_!QS_P H9?C)_P!P3_T^:?7V]7Q#_P ''/\ RAE^,G_<
M$_\ 3YI];8?^+'U7Y@?RRT445],:!17Z3?\ !K;\%?!OQW_X* ^,-(\<>$?#
M/C+2;?X?7MY%9:[I<&HV\4ZZEIB+*L<RLH<*[J& R [#.":_>S_AW'^SS_T0
M?X,_^$3IO_QFN&OCE2GR-$\Q_';76?"+X!^.OV@-;GTWP'X+\6>-M1M8O/FM
M= TBXU*:&/(&]DA1F5<D#)&,D5_7YX0_8B^"_P /=3CO= ^$/POT.\A<21SZ
M?X5L;:5&'1@R1 @CU%>H5SRS3^6/XAS'\ZO["7_!J_\ &+XW:S8:M\9;RU^%
M'A'S4DFL(YHK[7[Z+]TY6-(RT-OO1I%WS.9(G3YK=QU_=S]D+]CWX?\ [#'P
M0T_X?_#;0HM$T&Q=IY6+>9=:E<N )+JYE/S2S/M4%CPJHB*%1$1?3J*X:V*J
M5?BV[$W"BBBN< K/\6?\BKJ?_7I+_P"@&M"L_P 6?\BKJ?\ UZ2_^@&@#^)>
MBBBOK#0]Z_X)9?\ *2W]G_\ [*'H7_I?#7]?U?R _P#!++_E);^S_P#]E#T+
M_P!+X:_K^KQLS^->A,@K\P?^#M'P[=:W_P $S?#MS;QM)#H_Q T^[N6 SY<9
ML=0A!/I\\R#\17Z?5\H_\%QO@S>?'G_@D]\;M#L+B"WNK/01KX:568.FFW$6
MHR1J%!.]X[5T7MN<9P,FN+#RY:L7YDG\FM%%%?3&A^CO_!K'\7[7X:_\%5K/
M1;BUN+B;XA>%=4\/VTD9&VVDC$6I%WSSM*:>Z<<[G7MFOZ6Z_C+_ &2/VBM3
M_9(_:=\!_$S25O);SP3K=MJK6UM>M9-J$,<@,]H95!*QSP^9"_RL"DK JP)!
M_L7^%_Q*T3XS?#7P_P",/#5\-2\.^*M-M]7TN[$3Q?:K6>-98I-D@5UW(RG:
MZAAG! ((KQ<RIM34^Y,C=HHHKS20HHHH **** "BBB@ HHHH ^>/^"EK^7\"
M]);_ *CT(_\ )>XKX>-U7VW_ ,%.Y?*^ FD?]A^'_P!)[FOA(W5?@?B%&^<2
M_P ,3^H/"FG?(8O^]+\S0-UQ3?M54#=TANZ^'Y3]*]B?HE_P3^\11ZW^S/I<
M$8^;2[JYM9#GJQE:;^4HKVJOG#_@E_)YGP"U<_\ 4P3?^D]M7T?7]+<+U'/*
M<.W_ ")?=I^A_'O&E%4L]Q<(_P \G][N_P 6%%%%>\?+A1110 5\0_\ !QS_
M ,H9?C)_W!/_ $^:?7V]7Q#_ ,''/_*&7XR?]P3_ -/FGUMA_P"+'U7Y@?RR
MT445],:'ZF_\&C'_ "DB\;?]DUOO_3II5?T5U_.I_P &C'_*2+QM_P!DUOO_
M $Z:57]%=>#F'\8B6X4445PB"BBB@ HHHH *S_%G_(JZG_UZ2_\ H!K0K/\
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MQG;N!&<?C0!_$?17[G?\0<FC_P#1?]2_\(Y/_DRC_B#DT?\ Z+_J7_A')_\
M)E?0?7J'?\&7='Y5_P#!++_E);^S_P#]E#T+_P!+X:_K^K\C_P!E_P#X-4=+
M_9J_:1\!?$2/XW:AK$G@;Q!8Z\MBWA5(%O#;3I,(C)]K;9NV8W;3C.<&OUPK
MS<=6A4DG!BD%%%%<)(5^?_\ P6"_X(*^"_\ @I4]QXV\.7EMX'^,5O9>0FJ>
M5_Q+_$/EH!!'J"*"VY0HC6Y0&1(R RS+'%&GZ 45I3J2A+FB!_&W^UI^Q/\
M%']AOXBMX7^*'@_5?"^H,6^R3S)YEEJ:A48O;7*9BG4"1-WEL2C-M8*P*CRN
MO[5_BE\)/"OQQ\%W7AOQIX;T'Q9X?O"K3Z;K%A%>VDK*P9&,<BLI*L 0<9!
M(P17YJ?M1_\ !IY\!_BN)KOX:>(/%7PFU)Q$D5N)#KNDQA3\[&&X<7)=QW^U
M!5(X3M7K4<RB]*FA7,?SIT5^J?Q/_P"#2']H#PUJ.I/X7\:?"_Q1IENQ^Q>=
M>7>GW]XF/XH6MWBC;/;SV'^U7ADW_!N'^V9%,RK\'ED56(#KXLT3:WN,W@//
MN :ZXXJD]I(JY\/T5]U:!_P;9_MC:SJ\-M<?"RSTF&5L-=W7BK2&AA'JPBN7
M?'^ZI->]?"[_ (-$/CAKOB&S7QA\1/ACX;T68$W,^FR7NJWUOZ!8&@@C<_\
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M72Z+H^7*>2\C*CS[@05V!QAAG#NAP1FO6*^3?V?O%1_:J_;E\1>-(Y/-\.^
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M1N['R[I-<M8EDWVTL;G$<\HVEBOS9QD C]XOV1?V*OAE^PC\-K[PC\*?#/\
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M /!7_P#X*KC_ ()1_"KPEXF/@,^//^$IU:32_LPUK^R_LVV$R[]_D3;LXQC
M]<]JWGS\M+V>^HST#Q#^Q]J%K_P2\OO@#I6LV=]JT?PMD^'UGJUU"UK;W$XT
MDV"7$B*9&C1FPY4%RH) +8Y_&S_@WJ_X*:^&_P#@GSX_\<?L\_'"RM_"&D^(
MO$#J=3U& 1KHNK*!9W%IJ);[D#>4B[VPD+I(7PDC/'^X/PB_:ET'QQ^R!X,^
M,7B>ZTCP'H/BCPOIOB:\?5-4CCL]'2\MXIA')<R"-"%:4)O8)N..!G%?!?\
MP4*_X)R? ;_@N9\*O&WQ0^!NMZ5J'Q8\)7$NA_V_I ,=AXCOK2WBD6RN6<+%
M/F&6&-+N-B%#1@R.D7EC&A-6E"KL^O9B1]N?L>_\$]_@[^P+I>MV?PD\%V_A
M&'Q(\,FILM]=7LMX8=_E;I+B61\)YLF #@;VXY->S5^1O_!J7^WSXF^.GP<\
M8?!OQAJ\VL/\,X;.Z\,3W3F2YCTN3?$]INQS%;ND7E[F+*MP(UQ'$BK^N588
MB$H5'&;NQ!117R7_ ,%4/VRC\"/AVO@O0;F:#Q=XLMBSSQ@#^S[ ED=PQZ22
M%6C7:,@"1LJRIGR\QQ]+!8>6)K;1_%]$O-GM\.Y#BLZS"GEV#7O3>_1+K)^2
M6K^Y:V/E7_@I;^UE'^T1\:O[+T>X$GA;PB9+.T=)$DCOIRV)KE64<HVU53YF
M!6,,,>817S<;@FJ!N_\ :IK77O7\_P".QE3%XB6)K?%)W_R7HEH?WYD>0X?*
ML!2R_"JT*:LO-[MOS;NWYLT#<4TS_P"<UGFZXZUZ=^R!^SO??M4_'32O"]L9
M(K#/VS5KE) C6MDC*)74E6^<[E1/E(WNN<+DC/#X>=:I&E35Y2=D=>/Q5#!8
M:>+Q,N6$$Y-]DM?^&[L^U/\ @CK^S7_8GA._^)VJ0K]JUH/I^C X.RV1\33#
M#'EY$V $*P$+$962ON"O$_C-^V/\+?V))_"GA'Q*WBO18]2%KI'A^+3?!>MZ
MO:W4K+(EO90SVEK-$]R5@<B#>9=J;MN""=;X3_MN_#'XV?'#7OAIX?\ $DDG
MQ \+Z59ZUJOA^_TN\TW4+*TNX89X9&BN8HVR$N(/,09>%I5214<[:_H+*,J6
M!P<,/!;+5]WU?W_A9'\ \6<15L\S6KF573F?NK^6*TBODM^[N^IZM17F'[*/
M[9?PU_;@\!:EXH^%OB:/Q9H.CZK+HEU>1V5S:HEW''%*\8$\:%P$FB8.H*'=
MPQP<>GUZ,HM.S/FPHHHI ?F!\6/V$OCE\4OB?XA\22^!WA;7=1GOA$VMV+F%
M9)&94SY_(4$*/8"OT_HHKQ,GR&AETJDZ,I2=1IOF:Z7VLEW9]AQ3QKC,^IT*
M6*IPA&BFHJ"DM&HK7FE+;E5MNM[A1117MGQY^5O_  4__P"";WQH_:(_X+<?
ML]_%[P=X-_MCX=^!W\,G6]6_M>QM_L0M-<N+JX_<RS+,^R%U?Y$;=G"Y;(K]
M4J**TJ57))/H!^+_ /P;H_\ !)S]H#]A']MKQ1XN^*W@'_A%?#NI>"+O1[>[
M_MS3;[S+I[_3Y5CV6UQ(XS'!*=Q4+\N,Y(![[P9_P30^-VD_\'*$WQ^N/!/E
M_"1K^\F&O?VQ8'*2>'I;-#]G$_VCFX94_P!5D9R?EYK]8J*VEBIN3D[:JP[G
MYI_\')/_  3_ /BY^WU\*?A?IOPE\)?\)9?>'=6O;G4(_P"U+*P^SQR0QJC9
MN9H@V2I&%)(QS7RG\,OAQ_P6 ^#GPV\/^$?#=G_9OAWPKIMMH^EVGG>"IOLM
MK;Q+%#'OD9G;;&BC<[%CC)).37[L444\4XPY.5->:$?,/QB^%GQ6^./_  1_
MU[P;XDL?[4^-7BCX82:7JEGYUG!]IUN;3]DR;XV6U7,Y891A$,\$+BO"?^"!
M'_!.[QS^RY_P3]^(WPP^.G@N'27\:>)K^2XTF;4;6^CO]-N=-L[9PSVLLBA7
M\N9"I8-@9P 03^BE%9^VERN"V;N%S\D_^#>[_@G!^T5_P36_:B^*^B?$#PCI
M=M\-?%&G*D7B&UU2SNAJ-[8W16S>*-)_/CAE@N;M\2PJW$0;805+?A+_ ,$]
M/VBO$/\ P<>7W[1?B[X=V>A?#6#5M4AMM5BUNPF6XL8M&GTJPF$"W#SAYD6W
M=@R#:7;(7&!^MU%7+%2<G*RNU8+GY/\ _!R3_P $L/BI^W3\0/A'XJ^"_@&/
MQ-XBT2RU'3M?OTU>RT^6*W62VEL8R;J>+<%DDOF&S)!=MV,K7L'_  <-_L:?
M%#]OW]A3P?X7^%WA&;7?$UIXSLM;N],FU*RLI+2V73[^)RTDTRPLRR3Q*0DC
M9+9&5!-?H!12CB)+E_N[ ?,?_!&W]GKQA^RG_P $U_AC\/\ Q]H_]@^+O#T%
M\FH6'VJ"Z^SF34;J9/WD+O&V8Y$;Y6.,X.""!].445C*3E)R?4#^>_P[_P $
MRO\ @H3^RE^VQ\3OB;\$?!/]@WGBW4M5MXM2_MCPU=?:M.N;\7('E7<[A-QB
MA;)17&W'&6!^[/\ @E%_P\._X:@N/^&HO^2:_P!B7/E_\BU_Q_\ F0^3_P @
M[]_]SS>OR>O.*_22BNBIBG-6<5ZVU _+G_@X-_X(U^/_ -N;Q5X3^,'P;NFN
M_B-X/L8=&FT1]0CL7O;5+IYX)[2=RB17$,EQ,S>9(H=,%65XPDOR+\4_^"4?
M_!0__@J1\6O ^E_M%S:?H_ASP]+.L>OWMQH+1Z+!.8C<LEMICB2>5UACVJP"
MED4&2)27'] %%%/&3A%15M-GU0[F/\// 6D_"KP!H?A?0+./3M"\-Z?;Z5IU
MHA)6VMH(UBBC&><*BJ.?2OS"U/\ X)N?&FX_X.7U_:"3P9N^$(EC;^WO[7L>
M@\,+8G_1O.^T_P#'R#'_ *K_ &ON_-7ZJT5C3JRA>W56$%?D3_P;=?\ !,#X
MY_L#_&KXE:M\6O __")Z?X@T2VL["7^V=/OO/E2<NR[;:>1EPO.6 'O7Z[44
M0K.,7!=0/S1_X.&/^".'BK_@HYX?\(^-OA?%H,GQ \$V]S87>GWCBUF\06+D
M2111W+'RUDAE$A1)=B,+N4F1"H5_BSXI_P#!+;_@HU_P4S\=> ?"_P"T#-!I
MOA'P_<R[-;O[[06AT:.1$\Z5H--D$UU*RPJJ!P?G;!>)7DD'] -%;4\9.$5%
M):;=T.YY7J7['_A74_V*6^ KRZI_PA;>#!X&6<R1M?QV2V0LUE#LA3SUC 8.
M8RH< [>U?BO\,O\ @F5_P4F_X)LZ[XX\"_ 2_;4O >L7HG&I:?JNB+::G^ZV
MBYBM]1D\ZSN"C+'(8U4EH5'F2K%%)7[^45-+$2A=:-/N(_.W_@WX_P""0OB/
M_@FE\,?%7B#XA3:8WQ!^(*V8FL+*5;A-!M(49Q;M,% :9I)F\WRV>+]S%L9@
M-Q_1*BBLZE1SDY2W QOB#KVJ>&/!>I7^BZ%<>)M6MX2UII<-S#:M>2' 53+*
MRHBY.68DD*"0K-A3^5GQ-_X)]_M)?%_Q]JWB;7O!\E]J^LW#7%Q*VN:>1D\!
M5!N#M15 55Z*JJ!P!7ZV45\_G&0T<RY57G)*/1-)7[NZ>O\ 7<^ZX-X^QG#+
MJ3P%&G*=2R<IJ3=E]E6G%)7U>EV]V[*WXZG_ ()9?'S_ *$/_P K>G?_ "12
M'_@EC\?#_P R'_Y6]._^2*_8NBO#_P!0<O\ YY_?'_Y$^[_XF"XB_P"?%#_P
M&I_\L/QS/_!+#X^?]"&?_!WIW_R17Z*?\$]_V1(OV2_@E%;WJ%O%GB$1WNN.
M2C>3(%^2V4KD%(@S#.YMSM(P.U@H]XHKU,IX6P>7UO;TN9RM9<S3MZ62/E^+
MO%C.N(<%]0Q:A"G=-J"DN:VR?-*6B>MM-4GT1\V_\%%O@'XM^.^K?L]R^%-)
M_M6/P/\ &'1?%6MG[5#!]BTVWMKY)I_WCKOVM-&-B;G.[A2 <?/?[5?_  3Y
M^-'CW]H3XN^//AS)_P (SXA\4>*+?1=.U8ZQY/G>&M4\,:=H^JW*QQ3*?-L[
MRVMKU%D*.6TH>7N+J'_1:BOJH5I1V/S(^3O^"2W['^L?L5^#_C7X:O?#<?A;
MP]JWQ7U;5_"-I'>17*/H;6MC!9N"DCL@VV[+LE(D&SY@,@GZQHHK.<G)\S *
M***D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
